Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemoradiotherapy versus placebo plus chemoradiotherapy in limited-stage small cell lung cancer
NL-OMON61152Phase 3Active, not recruiting
- Sponsor
- Henlius
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in small cell lung cancer (SCLC), sponsored by Henlius. Started Apr 2024; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61152.